{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:05:35Z","timestamp":1762956335526,"version":"3.44.0"},"reference-count":32,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,4,2]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec id=\"s1\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Methotrexate (MTX) is currently the recommended first-line therapy for treating psoriatic arthritis (PsA), despite lacking clear evidence. No estimates of efficacy of MTX in usual care and no clear MTX responsive clinical or laboratory variables are currently available. This study describes the response to MTX monotherapy in newly diagnosed patients with PsA in usual care. Second, we compared clinical variables and cytokine profiles in patients responding and not responding to MTX monotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s2\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used data collected in the Dutch southwest Early Psoriatic Arthritis cohoRt study to select patients with PsA with oligoarthritis or polyarthritis, and at least 1 year follow-up. We analysed disease activity at 6 months of patients who started MTX monotherapy and still used MTX monotherapy 1 year after diagnosis. Cytokine profiles were determined at baseline and after 3 and 6\u00a0months with a bead-based multi-immunoassay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s3\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 219 patients of which 183 (84%) patients started MTX monotherapy within 6 months after diagnosis. 90 patients used MTX monotherapy throughout the first year of which 44 patients (24%) reached minimal disease activity(MDA) at 6\u00a0months, decreasing to 33 patients (18%) after 1 year. Non-responders had significantly higher concentrations of interleukin (IL) 23 and IL-10 before and during MTX therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"s4\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results showed that only 18% of patients with PsA are in sustained MDA after 1 year of MTX monotherapy and non-responders more often had IL-23-driven disease. Our results indicate the need for more treat-to-target and personalised therapy strategies in PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001175","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T11:37:09Z","timestamp":1594813029000},"page":"e001175","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4618-6827","authenticated-orcid":false,"given":"Hannah","family":"den Braanker","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands"},{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Wervers","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana M C","family":"Mus","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka S","family":"Bangoer","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Davelaar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"Luime","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilja","family":"Tchetverikov","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M W","family":"Hazes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Lubberts","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc R","family":"Kok","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.1","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090313312074000_6.2.e001175.2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.3","DOI":"10.1093\/rheumatology\/kes001"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.4","DOI":"10.1016\/S0140-6736(15)00347-5"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.5","DOI":"10.3899\/jrheum.150614"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.6","DOI":"10.1136\/annrheumdis-2018-214746"},{"key":"2025090313312074000_6.2.e001175.7","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.8","DOI":"10.3899\/jrheum.160111"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.9","DOI":"10.1002\/art.40726"},{"key":"2025090313312074000_6.2.e001175.10","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23571","article-title":"Burden of psoriatic arthritis according to different definitions of disease activity: comparing minimal disease activity and the disease activity index for psoriatic arthritis","volume":"70","author":"Wervers","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.11","DOI":"10.1002\/art.23568"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.12","DOI":"10.1159\/000250839"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.13","DOI":"10.1093\/rheumatology\/34.12.1167"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.14","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090313312074000_6.2.e001175.15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.16","DOI":"10.1038\/nrrheum.2015.53"},{"doi-asserted-by":"crossref","unstructured":"Al-Mossawi MH , Chen L , Fang H , et al. Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis. Nat Commun 2017;8:1510.","key":"2025090313312074000_6.2.e001175.17","DOI":"10.1038\/s41467-017-01771-2"},{"key":"2025090313312074000_6.2.e001175.18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000471798","article-title":"New interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology"},{"key":"2025090313312074000_6.2.e001175.19","first-page":"305","article-title":"Vascular endothelial growth factor in patients with psoriatic arthritis","volume":"25","author":"Fink","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313312074000_6.2.e001175.20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/phar.1938","article-title":"Cytokine biomarkers of disease activity and therapeutic response after initiating methotrexate therapy in patients with juvenile idiopathic arthritis","volume":"37","author":"Funk","year":"2017","journal-title":"Pharmacotherapy"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.21","DOI":"10.1007\/s00296-011-1867-1"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.22","DOI":"10.1136\/ard.59.4.311"},{"doi-asserted-by":"crossref","unstructured":"Zhong W , Zhao L , Liu T , et al. IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide. Sci Rep 2017;7:41143.","key":"2025090313312074000_6.2.e001175.23","DOI":"10.1038\/srep41143"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.24","DOI":"10.1038\/nrrheum.2016.175. PubMed PMID: 27784891."},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.25","DOI":"10.1136\/ard.2003.014738"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.26","DOI":"10.1109\/TAC.1974.1100705"},{"unstructured":"R: a language and environment for statistical computing [program] . Vienna, Austria: R Foundation for Statistical Computing, 2019.","key":"2025090313312074000_6.2.e001175.27"},{"unstructured":"gplots: various R programming tools for plotting data [program]. R package version 3.0.3 version, 2020.","key":"2025090313312074000_6.2.e001175.28"},{"doi-asserted-by":"crossref","unstructured":"Elghandour TM , Youssef Sel S , Aly DG , et al. Effect of narrow band ultraviolet B therapy versus methotrexate on serum levels of interleukin-17 and interleukin-23 in Egyptian patients with severe psoriasis. Dermatol Res Pract 2013;2013:618269.","key":"2025090313312074000_6.2.e001175.29","DOI":"10.1155\/2013\/618269"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.30","DOI":"10.1007\/s10165-009-0217-6"},{"doi-asserted-by":"publisher","key":"2025090313312074000_6.2.e001175.31","DOI":"10.1038\/nri2711"},{"key":"2025090313312074000_6.2.e001175.32","first-page":"496","article-title":"Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment","volume":"28","author":"Seitz","year":"2001","journal-title":"J Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001175","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:31:29Z","timestamp":1756931489000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/rmdopen-2020-001175"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001175","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}